[SCHEDULE 13G/A] Praxis Precision Medicines, Inc. SEC Filing
Adage Capital Management and two principals report beneficial ownership of 2,374,085 shares of Praxis Precision Medicines, Inc. (PRAX), representing 11.28% of the 21,045,781 shares outstanding as of July 31, 2025. The filing is a Schedule 13G/A indicating the stake is held in the ordinary course of business and not to influence control. The reported holdings are held directly by Adage Capital Partners, L.P. and are disclosed by Adage Capital Management, L.P., Robert Atchinson and Phillip Gross, each showing shared voting and dispositive power over 2,374,085 shares and no sole voting or dispositive power. The filing cites the issuers principal executive office in Boston and uses the CUSIP 74006W207.
Adage Capital Management e due soci dichiarano la propriet脿 beneficiaria di 2.374.085 azioni di Praxis Precision Medicines, Inc. (PRAX), pari all'11,28% delle 21.045.781 azioni in circolazione al 31 luglio 2025. La comunicazione 猫 un Schedule 13G/A che specifica come la partecipazione sia detenuta nell'ordinario svolgimento dell'attivit脿 commerciale e non abbia l'intento di influenzare il controllo. Le azioni sono detenute direttamente da Adage Capital Partners, L.P. e la posizione 猫 divulgata da Adage Capital Management, L.P., Robert Atchinson e Phillip Gross, ognuno dei quali dichiara di avere la potest脿 di voto e dispositiva condivisa su 2.374.085 azioni e di non detenere poteri di voto o dispositivi in via esclusiva. Il documento indica la sede principale dell'emittente a Boston e utilizza il CUSIP 74006W207.
Adage Capital Management y dos socios informan la propiedad beneficiaria de 2.374.085 acciones de Praxis Precision Medicines, Inc. (PRAX), que representan el 11,28% de las 21.045.781 acciones en circulaci贸n al 31 de julio de 2025. El documento es un Schedule 13G/A que aclara que la participaci贸n se mantiene en el curso ordinario del negocio y no pretende influir en el control. Las participaciones est谩n en posesi贸n directa de Adage Capital Partners, L.P. y son divulgadas por Adage Capital Management, L.P., Robert Atchinson y Phillip Gross, cada uno de los cuales declara tener poder de voto y de disposici贸n compartidos sobre 2.374.085 acciones y no tener poder de voto o disposici贸n exclusivo. La presentaci贸n se帽ala la oficina principal del emisor en Boston y utiliza el CUSIP 74006W207.
Adage Capital Management鞕� 霊� 氇呾潣 甏�瓿勳瀽臧� Praxis Precision Medicines, Inc.(PRAX)鞚� 2,374,085欤检棎 雽�頃� 鞁れ鞝� 靻岇湢毳� 氤搓碃頄堨溂氅�, 鞚措姅 2025雲� 7鞗� 31鞚� 旮办 氚滍枆欤检嫕 21,045,781欤检潣 11.28%鞐� 頃措嫻頃╇媹雼�. 鞚� 氤搓碃靹滊姅 Schedule 13G/A搿�, 歆�攵勳澊 韱奠儊鞝侅澑 靷梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 頄夓偓 鞚橂弰臧� 鞐嗢潓鞚� 氚濏灆雼堧嫟. 氤搓碃霅� 歆�攵勳潃 Adage Capital Partners, L.P.臧� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅� Adage Capital Management, L.P., Robert Atchinson 氚� Phillip Gross臧� 臧侁皝 鞚措ゼ 瓿奠嫓頃橁碃, 臧侅瀽電� 2,374,085欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 鞐嗠嫟瓿� 旮办灛頄堨姷雼堧嫟. 鞝滌稖靹滊電� 氚滍枆鞚胳潣 氤胳偓臧� 氤挫姢韯挫棎 鞛堨潓鞚� 鞏戈笁頃橁碃 CUSIP 74006W207鞚� 靷毄頃╇媹雼�.
Adage Capital Management et deux dirigeants d茅clarent la propri茅t茅 b茅n茅ficiaire de 2 374 085 actions de Praxis Precision Medicines, Inc. (PRAX), soit 11,28 % des 21 045 781 actions en circulation au 31 juillet 2025. Le d茅p么t est un Schedule 13G/A pr茅cisant que la position est d茅tenue dans le cours normal des activit茅s et n'a pas pour but d'influencer le contr么le. Les avoirs sont d茅tenus directement par Adage Capital Partners, L.P. et sont divulgu茅s par Adage Capital Management, L.P., Robert Atchinson et Phillip Gross, chacun d茅clarant d茅tenir la puissance de vote et de disposition conjointe sur 2 374 085 actions et ne d茅tient aucun pouvoir de vote ou de disposition exclusif. Le dossier indique le si猫ge principal de l'茅metteur 脿 Boston et utilise le CUSIP 74006W207.
Adage Capital Management und zwei Personen melden wirtschaftliches Eigentum an 2.374.085 Aktien von Praxis Precision Medicines, Inc. (PRAX), was 11,28 % der 21.045.781 ausstehenden Aktien zum 31. Juli 2025 entspricht. Die Einreichung ist ein Schedule 13G/A und gibt an, dass die Beteiligung im normalen Gesch盲ftsbetrieb gehalten wird und nicht darauf abzielt, die Kontrolle zu beeinflussen. Die gemeldeten Best盲nde werden direkt von Adage Capital Partners, L.P. gehalten und durch Adage Capital Management, L.P., Robert Atchinson und Phillip Gross offengelegt; jeweils wird gemeinsame Stimm- und Verf眉gungsgewalt 眉ber 2.374.085 Aktien angegeben, ohne alleinige Stimm- oder Verf眉gungsrechte. Die Einreichung nennt den Hauptsitz des Emittenten in Boston und verwendet die CUSIP 74006W207.
- None.
- None.
Insights
TL;DR: A prominent investment manager reports an 11.28% passive stake in PRAX, a sizable minority position that must be monitored by holders.
Adages disclosure shows a 2.37 million-share position held through affiliated partnerships with shared voting and dispositive power, consistent with institutional accumulation disclosed on a Schedule 13G/A for passive investors. The filing references 21,045,781 shares outstanding, providing a clear percentage basis. This level of ownership exceeds 5% and is material to shareholders because it represents a significant minority stake without stated intent to change control, as per the certification language. The structure identifies the reporting entities and individual principals, clarifying attribution of voting and disposition rights.
TL;DR: Adage and two named principals hold an 11.28% position with shared control indicators; filing signals passive intent under Schedule 13G/A.
The Schedule 13G/A classifies the position as held in the ordinary course of business and not for the purpose of influencing control, which is important for governance expectations. The disclosure names Adage Capital Management, L.P., and principals Robert Atchinson and Phillip Gross, and documents shared voting and dispositive power only. For boards and investors, a reported >10% stake is material for monitoring potential engagement but the form asserts passive intent, limiting immediate governance implications disclosed in this filing.
Adage Capital Management e due soci dichiarano la propriet脿 beneficiaria di 2.374.085 azioni di Praxis Precision Medicines, Inc. (PRAX), pari all'11,28% delle 21.045.781 azioni in circolazione al 31 luglio 2025. La comunicazione 猫 un Schedule 13G/A che specifica come la partecipazione sia detenuta nell'ordinario svolgimento dell'attivit脿 commerciale e non abbia l'intento di influenzare il controllo. Le azioni sono detenute direttamente da Adage Capital Partners, L.P. e la posizione 猫 divulgata da Adage Capital Management, L.P., Robert Atchinson e Phillip Gross, ognuno dei quali dichiara di avere la potest脿 di voto e dispositiva condivisa su 2.374.085 azioni e di non detenere poteri di voto o dispositivi in via esclusiva. Il documento indica la sede principale dell'emittente a Boston e utilizza il CUSIP 74006W207.
Adage Capital Management y dos socios informan la propiedad beneficiaria de 2.374.085 acciones de Praxis Precision Medicines, Inc. (PRAX), que representan el 11,28% de las 21.045.781 acciones en circulaci贸n al 31 de julio de 2025. El documento es un Schedule 13G/A que aclara que la participaci贸n se mantiene en el curso ordinario del negocio y no pretende influir en el control. Las participaciones est谩n en posesi贸n directa de Adage Capital Partners, L.P. y son divulgadas por Adage Capital Management, L.P., Robert Atchinson y Phillip Gross, cada uno de los cuales declara tener poder de voto y de disposici贸n compartidos sobre 2.374.085 acciones y no tener poder de voto o disposici贸n exclusivo. La presentaci贸n se帽ala la oficina principal del emisor en Boston y utiliza el CUSIP 74006W207.
Adage Capital Management鞕� 霊� 氇呾潣 甏�瓿勳瀽臧� Praxis Precision Medicines, Inc.(PRAX)鞚� 2,374,085欤检棎 雽�頃� 鞁れ鞝� 靻岇湢毳� 氤搓碃頄堨溂氅�, 鞚措姅 2025雲� 7鞗� 31鞚� 旮办 氚滍枆欤检嫕 21,045,781欤检潣 11.28%鞐� 頃措嫻頃╇媹雼�. 鞚� 氤搓碃靹滊姅 Schedule 13G/A搿�, 歆�攵勳澊 韱奠儊鞝侅澑 靷梾 瓿检爼鞐愳劀 氤挫湢霅橁碃 鞛堨溂氅� 歆�氚瓣秾 頄夓偓 鞚橂弰臧� 鞐嗢潓鞚� 氚濏灆雼堧嫟. 氤搓碃霅� 歆�攵勳潃 Adage Capital Partners, L.P.臧� 歆侅爲 氤挫湢頃橁碃 鞛堨溂氅� Adage Capital Management, L.P., Robert Atchinson 氚� Phillip Gross臧� 臧侁皝 鞚措ゼ 瓿奠嫓頃橁碃, 臧侅瀽電� 2,374,085欤检棎 雽�頃� 瓿惦彊 鞚橁舶甓� 氚� 觳橂秳甓岇潉 氤挫湢頃橁碃 雼弲 鞚橁舶甓岇澊雮� 觳橂秳甓岇潃 鞐嗠嫟瓿� 旮办灛頄堨姷雼堧嫟. 鞝滌稖靹滊電� 氚滍枆鞚胳潣 氤胳偓臧� 氤挫姢韯挫棎 鞛堨潓鞚� 鞏戈笁頃橁碃 CUSIP 74006W207鞚� 靷毄頃╇媹雼�.
Adage Capital Management et deux dirigeants d茅clarent la propri茅t茅 b茅n茅ficiaire de 2 374 085 actions de Praxis Precision Medicines, Inc. (PRAX), soit 11,28 % des 21 045 781 actions en circulation au 31 juillet 2025. Le d茅p么t est un Schedule 13G/A pr茅cisant que la position est d茅tenue dans le cours normal des activit茅s et n'a pas pour but d'influencer le contr么le. Les avoirs sont d茅tenus directement par Adage Capital Partners, L.P. et sont divulgu茅s par Adage Capital Management, L.P., Robert Atchinson et Phillip Gross, chacun d茅clarant d茅tenir la puissance de vote et de disposition conjointe sur 2 374 085 actions et ne d茅tient aucun pouvoir de vote ou de disposition exclusif. Le dossier indique le si猫ge principal de l'茅metteur 脿 Boston et utilise le CUSIP 74006W207.
Adage Capital Management und zwei Personen melden wirtschaftliches Eigentum an 2.374.085 Aktien von Praxis Precision Medicines, Inc. (PRAX), was 11,28 % der 21.045.781 ausstehenden Aktien zum 31. Juli 2025 entspricht. Die Einreichung ist ein Schedule 13G/A und gibt an, dass die Beteiligung im normalen Gesch盲ftsbetrieb gehalten wird und nicht darauf abzielt, die Kontrolle zu beeinflussen. Die gemeldeten Best盲nde werden direkt von Adage Capital Partners, L.P. gehalten und durch Adage Capital Management, L.P., Robert Atchinson und Phillip Gross offengelegt; jeweils wird gemeinsame Stimm- und Verf眉gungsgewalt 眉ber 2.374.085 Aktien angegeben, ohne alleinige Stimm- oder Verf眉gungsrechte. Die Einreichung nennt den Hauptsitz des Emittenten in Boston und verwendet die CUSIP 74006W207.
FAQ
How many Praxis (PRAX) shares does Adage Capital report owning?
What percentage of PRAX does the reported holding represent?
Which entities and individuals filed the Schedule 13G/A for PRAX?
Does the Schedule 13G/A indicate intent to influence control of Praxis?
Who has voting and dispositive power over the reported PRAX shares?
